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Text
Currently, Non-Communicable Diseases (NCDs) have been 
increasing in the world. Among them, the crucial issues in focus 
would be the clinical management of diabetes and chronic kidney 
disease (CKD).1 The authors and colleagues have been involved in 
the practice of diabetes for years.2 Particularly, we have continued 
clinical and research studies on low carbohydrate diet (LCD). For 
actual nutritional therapy, three kinds of LCDs were developed and 
educated, which are super-, standard- and petite-LCDs. Furthermore, 
we have treated many patients with CKD and hemodialysis (HD) in our 
hospital.3 From the circumstances mentioned above, there are recent 
beneficial topics concerning DM and CKD. These were 1) relaxed 
restrictions on metformin use for CKD, which is partly from using 
estimated glomerular filtration rate (eGFR) and pathophysiological 
research accumulation, 2) improvement of combined renal outcomes 
with SGLT2 inhibitor and 3) adequate administration of erythropoiesis 
stimulating agent (ESA) on dialysis patients. These three topics will 
be introduced in this article as possible pharmacotherapy for CKD 
and diabetes.
Firstly, metformin (dimethylbiguanide) has been first-line oral 
hyperglycemic agent (OHA) to type 2 diabetes mellitus (T2DM).4 
It has the ability to counter insulin resistance and to decrease blood 
glucose without increased weight or risk of hypoglycemia, which 
is beneficial for clinical practice. It was proved to have long-term 
cardiovascular benefits according to UK Prospective Diabetes Study 
(UKPDS).5 These data had provided a new rationale to give metformin 
for initial therapy to T2DM.
Among many OHAs, metformin had been previously the only 
one that had shown an inhibitory effect on cardiovascular events.6 
Formerly, the clinical use of metformin was restricted for patients 
with CKD. Its reason included the concerns over metformin-
associated lactic acidosis. There are several data to suggest that 
metformin may bring lower risk of stroke, myocardial infarction and 
all-cause mortality in T2DM and CKD.7 After that, several results 
concerning metformin and CKD were conflicting, and there were 
some reports with safer prescribing of metformin at different stages of 
CKD. A recent large-scale cohort study showed the evidence for safe 
use of metformin in mild to moderate renal impairment (estimated 
glomerular filtration rate [eGFR] 30–60 mL/min/1.73m2). However, 
administration of metformin to severe level (eGFR< 30) remains a 
controversial issue.7 
There was a retrospective observational cohort study for 10,426 
patients with type 2 diabetic kidney disease (DKD).8 As a result, 
metformin usage has decreased the risk of all-cause mortality 
and incident end-stage renal disease (ESRD). However, further 
randomized controlled trials (RCTs) will be necessary to change the 
administration of metformin worldwide.8 
 Secondly, several SGLT2 inhibitors were investigated in the 
light of renal function. There have been several mega studies for 
administrating of SGLT2 inhibitors.9 They include i) Canagliflozin 
cardiovascular Assessment Study (CANVAS), ii) Canagliflozin and 
Renal Events in Diabetes with Established Nephropathy Clinical 
Evaluation (CREDENCE), iii) Empagliflozin Cardiovascular 
Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing 
Excess Glucose (EMPA-REG OUTCOME) study, iv) Dapagliflozin 
Effect on Cardiovascular Events (DECLARE)-TIMI 58. 
The CANVAS Program randomly assigned 10,142 participants 
with T2DM to canagliflozin or placebo.10 In the total cohort, the 
primary end point was reduced with canagliflozin compared with 
placebo (hazard ratio [HR] 0.86). Renal outcome was reduced (HR, 
0.59) and heart failure hospitalization was also reduced (HR, 0.68). 
Thus, Canagliflozin reduced moderately cardiovascular and renal 
outcomes across the primary and secondary prevention groups.10 
Successively, a series of CANVAS study revealed a beneficial efficacy 
on cardiovascular and also renal outcomes in T2DM.11 In contrast, the 
data revealed rather elevated risk ratio for the amputation of lower 
extremities.12
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Abstract
The authors and colleagues have been involved in Non-Communicable Diseases (NCDs), 
especially including diabetes, chronic kidney disease (CKD) and hemodialysis. Some 
topics are described as possible therapy for CKD. (i) Metformin has inhibitory effect on 
cardiovascular events, and has an evidence for safe administration in mild to moderate 
renal impairment. (ii) Canagliflozin reduced moderately cardiovascular and renal outcomes 
across the primary and secondary prevention groups, from mega studies of CANVAS and 
CREDENCE. (iii) erythropoiesis stimulating agent (ESA) has been effective for improving 
anemia in HD for years. Some hypoxia-inducible factor (HIF) seems to be applied for 
clinical practice soon.
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Based on CANVAS results, further investigation was conducted 
with canagliflozin-based cardio-renal events as primary outcomes.13 
This study has been the CREDENCE Clinical Trials, which was a 
double-blind, randomized trial concerning canagliflozin as SGLT2 
inhibitor.13 Assigned subjects were T2DM patients with albuminuric 
CKD, who were provided canagliflozin. Their average age was 63 
years old (n=4401). The protocol included two groups, which were 
canagliflozin group and control group. 
As a result, relative risk of primary outcome showed 30% lower 
in canagliflozin group (HR 0.70).The time period for doubling level 
of serum creatinine was reduced from control by 40% (HR 0.60).The 
death from renal cause was reduced from control by 34% (HR 0.66). 
Furthermore, relative risk of ESKD was reduced by 32% (HR 0.68). 
Consequently, canagliflozin group revealed a reduced risk ratio of 
stroke, cardiovascular death and myocardial infarct (HR 0.80), and 
a reduced risk ratio of hospitalization from heart failure (HR 0.61).
On the other hand, there was no significant differences in adverse 
events (HR 0.87), or in the occurrence of the amputation (HR 1.11) 
and fracture (HR 0.98).13
Regarding the effect of SGLT2 inhibitors in renal failure, there 
was a systematic review and meta-analysis of randomized, controlled, 
cardiovascular or kidney outcome trials.14 The study covered 
canagliflozin (CANVAS Program and CREDENCE),11 empagliflozin 
(EMPA-REG OUTCOME),15,16 and dapagliflozin (DECLARE-TIMI 
58)17,18 with 38,723 subjects and 335 ESKD. The risk had reduced as 
ESKD (HR 0.65) and acute renal failure (HR 0.75). Thus, SGLT2 
inhibitors reduced the risk of dialysis and renal impairment, suggesting 
the preventing major kidney outcomes in T2DM.
Furthermore, there was a systematic review and meta-analysis 
for effect of SGLT2 inhibitor for T2DM and CKD from 7363 
participants in 27 studies.19 The risk was reduced by SGLT inhibitors 
in heart failure (RR 0.61), cardiovascular death, nonfatal myocardial 
infarction or nonfatal stroke (RR 0.81), and composite renal outcome 
(HR0.71). Thus, SGLT2 inhibitors are effective for reducing the risk 
of cardiovascular and renal exacerbation in T2DM and CKD.
From statistic point of view, there is a recent report from the United 
States Renal Data System (USRDS).20 It showed that approximately 
40% of CKD patients also have concomitant diabetes.20,21 As 
association of DM and CKD may increase mortality and morbidity, 
effective interventional strategy would be needed for protecting 
renal impairment, albuminuria, cardiovascular events.21 For the 
perspectives in the future, propensity score analysis method may be 
useful (Leyrat-2017).22 It can estimate the effect of a treatment, policy, 
or other intervention by accounting for the covariates that predict 
receiving the treatment.
Thirdly, erythropoiesis stimulating agent (ESA) will be described.
ESA has been effective for improving anemia in HD for years.23 As 
recombinant human erythropoietin is given, the target Hb level would 
be important. When comparing the level at 13.5g/dL vs 11.3g/dL, the 
former showed increased risk and no incremental improvement in the 
quality of life.23 When comparing short-acting ESAs vs long-acting 
ESAs, the latter users revealed 13% higher rate of deaths.24 There have 
been discussion concerning the target level and ESA type. As oral 
anti-anemic agents, a few kinds of hypoxia-inducible factor (HIF) will 
be planned to be introduced in the clinical practice in 2020.1 Further 
research development would be expected.
In summary, recent topics of metformin, SGLT2 inhibitor and ESA 
were summarized in this article. These factors are possible therapy for 
CKD. We hope that this description will help future medical practice 
and research.
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